Post

Radiation Biodosimetry Devices: Performance Testing and Documentation Requirements

This guidance applies to medical device systems intended to measure biological responses to unintended (non-therapeutic) radiation absorption. It specifically covers radiation biodosimetry devices used for reconstructing ionizing radiation dose received by individuals or populations using physiological, chemical, or biological markers found in humans. The guidance does not apply to devices measuring therapeutic radiation doses, long-term radiation exposure effects, or physical dosimeters.

  1. Develop comprehensive validation plan including analytical, pre-clinical, and clinical performance testing
  2. Submit pre-submission to FDA to discuss:
    • Clinical study design
    • Statistical analysis plan
    • Animal study protocols
    • Sample acquisition strategies
  3. Establish analytical performance through:
    • Accuracy studies
    • Precision studies
    • Interference testing
    • Stability testing
  4. Conduct animal studies to:
    • Bridge to human data
    • Evaluate confounding factors
    • Assess performance at doses/scenarios not possible in humans
  5. Perform clinical validation using:
    • Prospective studies when possible
    • Banked samples if analytes are stable
    • Appropriate controls and documentation
  6. Develop comprehensive labeling including:
    • Clear instructions for use
    • Limitations and warnings
    • Performance characteristics
    • Result interpretation guidance
  7. Prepare post-market testing plan for real-world emergency scenarios
  8. Submit complete electronic data package in appropriate format

Key Considerations

Clinical testing

  • Clinical validation studies should be performed using human samples when possible
  • Both prospective studies and banked samples can be used if analytes are stable
  • Basic demographic information and radiation exposure profiles must be documented
  • Studies should assess performance beyond claimed timeframes post-exposure
  • Limitations of clinical studies must be acknowledged and addressed

Non-clinical testing

  • Animal models can supplement human clinical data
  • Must justify animal model selection based on biological pathway similarities
  • Multiple animal models may be needed if single model is insufficient
  • Animal studies must comply with welfare regulations and GLP requirements
  • Animal studies should standardize husbandry conditions and timing of radiation exposure

Human Factors

  • Instructions must be appropriate for intended user (lay person vs healthcare provider)
  • Step-by-step procedures must be clearly outlined
  • Quality control procedures must be described
  • Training requirements must be specified for intended users

Software

  • Software documentation requirements based on “level of concern”
  • Must follow FDA software guidance for medical devices
  • Statistical analysis plans must be pre-specified
  • Electronic data should be provided in appropriate format

Labeling

  • Must include limitations, contraindications, and warnings
  • Must describe specimen collection and handling requirements
  • Must provide interpretation guidance for results
  • Must include performance characteristics summary
  • Must specify appropriate timeframes for testing post-exposure

Safety

  • Must assess risks of false positive and false negative results
  • Must evaluate impact on patient management decisions
  • Must consider risks in emergency/disaster scenarios

Other considerations

  • CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures
  • CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures
  • CLSI EP07-A2: Interference Testing in Clinical Chemistry
  • CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures
  • CLSI EP09-A3: Measurement Procedure Comparison and Bias Estimation Using Patient Samples
  • CLSI EP24-A2: Assessment of the Diagnostic Accuracy of Laboratory Tests Using ROC Curves
  • CLSI GP-14: Labeling of Home-Use In Vitro Testing Products

Original guidance

  • Radiation Biodosimetry Devices: Performance Testing and Documentation Requirements
  • HTML / PDF
  • Issue date: 2016-04-18
  • Last changed date: 2019-03-14
  • Status: FINAL
  • Official FDA topics: Radiation-Emitting Products, Medical Devices, Laboratory Tests, Emergencies, Premarket, IVDs (In Vitro Diagnostic Devices), Radiological Health
  • ReguVirta summary file ID: 57bcf94b87e2cdd72d928cd235ac5b46
This post is licensed under CC BY 4.0 by the author.